Introduction
Experimental evidence indicates that tissue remodeling, wound healing, and morphogenesis require communication between cells and the extracellular matrix (ECM). Because migration and differentiation of most cells are dependent on interactions with the ECM, considerable attention has been focused on macromolecules that facilitate cell attachment. Proteases, growth factors, and certain "adhesive" and "anti-adhesive" proteins have been implicated as regulators of cell adhesion and shape because of their association with the ECM and their effects on cell-surface contacts (1) (2) (3) . SPARC (osteonectin, BM-40, Mr 43 KD protein) is a member of a small family of related genes (including SC-1 and QRI) implicated in normal tissue morphogenesis and differentiation. Functionally, it has been grouped with tenascin and thrombospondin as an anti-adhesive protein (4.5) . SPARC is a highly conserved, secreted glycoprotein that exhibits restricted expression in adult and embryonic tissues (6) (7) (8) . It has been reported to diminish endothelial cell focal adhesions, affect matrix mineralization, modulate the progression of cells through the cell cycle, and regulate Supported by Grants GM-40711 (EHS) and CA-36250 (AMG) from Correspondence to: Peggy L. Porter, MD, Harborview Medical Cen- the National Institutes of Health.
ter, Dept. of Pathology, U -5 1 , 325 9th Ave., Seattle, WA 98195. and endothelial cells. Strong reactivity was found in fibrocytes and endothelial cells involved in tissue repair and in invasive malignant tumors, including those of the gastrointestinal tract, breast, lung, kidney, adrenal cortex, ovary, and brain. We conclude that SSP2 is a useful reagent for detection of SPARC in human tissue. Given the broad reactivity of malignant tissues, we propose that SPARC expression might contribute to some aspects of tumor progression. (J fistochem cytochem 43:791-800, 1995) KEY WORDS: SPARC; Monoclonal antibody; Immunocytochemistry; Human tissue; Cancer. neovascularization (9) (10) (11) (12) (13) (14) (15) (16) . The protein also induces the expression of certain metalloproteinases and Type I plasminogen activator inhibitor (PAI-I), enzymes that are important in the degradation of ECM components (13, 17) . The distribution of murine SPARC/osteonectin in vivo indicates a temporal and spatial regulation during development. In the adult, SPARC has been localized to areas of active morphogenesis and to cell populations that exhibit high rates of turnover, secretion, steroid production, and remodeling (6, 7, 18) .
Although information regarding the structure and potential functions of SPARC has increased significantly, relatively little is known about the expression and distribution of SPARC in humxi tissue, particularly with respect to disease processes. Many of the cell-matrix interactions in which SPARC is believed to participate, e.g., cell attachment to and detachment from cell surface or ECM components, turnover of the basement membrane, and cell locomotion, are potentially important components in the development of an invasive and metastatic cell population (19, 20) .
In this study we produced a monoclonal antibody (MAb) to a Ca*+-binding region of SPARC and used this highly specific reagent to examine the distribution of SPARC in human benign and malignant tissue. We demonstrate low levels of expression in normal human tissues, with a pattern of expression comparable to that previously observed in murine tissues. In contrast, there were significantly elevated levels of SPARC in malignant tissue. Because immunoreactive cells were observed in virtually all tumor types, 791 SPARC expression might serve to identdy a stage of transformation that is common to tumor progression in a wide variety oftissues.
Table 1. Production of SPARC by cells of normal human tirfue cells
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Materials and Methods
Prodaction of Hybridomas. Balblc mice were immunized against a synthetic peptide from Domain I of murine SPARC (SPARC peptide 1.1, amino acids 5-23) in accord with a standard immunization protocol. Briefly, three IP injections containing 400 pg of peptide were administered over a 4-week period. Spleens were removed and a fusion procedure was performed with NS-1 cells as previously described (21).
The titer and specificity of the MAb secreted into the culture medium by hybridoma cells were assessed by enzyme-linked immunosorbent assay (ELISA). Reactivity with other proteins was not observed, and the reactivity towards murine SPARC was inhibited by prior incubation of an ammonium sulfate fraction of antibody with the bovine or murine SPARC peptide 1.1. The MAb was not reactive on Western blots at dilutions ranging from 1:200 to 1:1500. However, it exhibited a high reactivity with murine parietal yolk sac (PYS-2) teratocarcinoma cells by immunofluorescence microscopy. Hybridoma ascites was produced from screened clones as previously described (21).
Characterization of Antibodies. The antibody was of the IgGl subclass and was titered against several rat and mouse tissues as described by Floege et al. (22) .
Radioimmune precipitation was performed according to Lane and Sage (IO), with minor modifications. [ 3'S]-Methionine-labeled proteins from the culture medium of human smooth muscle cells, human fetal fibroblasts, and PYS-2 cells were pre-incubated with 20 p1 of agarose beads coupled to anti-mouse IgG for 30 min at room temperature (RT). After removal of the beads by centrifugation, the primary antibodies [either anti-osteonectin (Hematologic Technologies; Essex Junction, VT). hybridoma supernatant containing antibodies against murine SPARC peptide 1.1, termed SSP2 and SSPJ, or affinity-purified guinea pig anti-bovine SPARC peptide 1.1 IgG] were added at a dilution of 1:100 to the radiolabeled supernatant proteins for 2 hr at RT, For an initial volume of 400 pl culture medium, 20 pl of anti-mouse IgG-agarose or 20 p1 of protein A-Sepharose was added to immune complexes for 30 min at RT. The beads were separated by centrifugation, the supernatants were discarded, and the beads were washed twice with PBS containing 0.05% Tween-20 and once subsequently with PBS. Immunoreactive proteins were solubilized by heating at 95°C for 5 min in 60 pl of SDS-PAGE buffer containing 50 mM dithiothreitol according to the method of Laemmli. The beads were removed from the solution by centrifugation and aliquots of the supernatant were quantified by scintillation counting before analysis by SDS-PAGE.
Immunohistological Studies. Absorption studies were performed on sections of Methyl-Carnoy's-fixed, deparaffinized monkey iliac artery tissue. Sections were immunostained with ascites designated SSP2 at a dilution of 1:2000 before and after pre-absorption with a 40-pM solution of the immunizing peptide. Unueated antibodies reacted with medial smooth muscle cells of the iliac arteries that displayed neointimal thickening; preabsorption eliminated all staining (not shown).
Hybridoma ascites fluids from the supernatant designated SSP2 were used for immunocytochemical studies. Because we were unable to demonstrate immunoreactivity in formalin-fixed material, we used tissue that was preserved in Methyl-Carnoy's fixative. Ascites fluids were assayed on sections from 118 deparaffinized adult and fetal human tissue blocks, selected from archival cases collected at the University of Washington from 1986 to 1991. Cases included a wide range of benign and malignant tissues (%bles 1 and 2). Six-pm sections were cut from the fixed tissue spechens and were deparaffinized in a series of xylene solutions. After sections were blocked with 10% H202, immunostaining was accomplished with the streptavidin-biotin-immunoperoxidase method as prcviously described (23.24). Hybridoma ascites fluids SSP2 were diluted to 1:2000 before use.
Sections from selected cases were also immunostained with anti-PCNA (proliferating cell nuclear antigen) MAb 19A2 (Coulter Laboratories; Hialeah, FL) for evaluation of proliferative rate.
Results

Anti-peptide MA6 SSP2 Reacts with Native SPARC
Native SPARC was precipitated by four different antibodies that included SSP2 (Figure 1 ). Culture media proteins from human smooth muscle cells were incubated with affinity-purified guinea pig anti-bovine SPARC peptide 1.1 IgG (Figure 1 
Distribution of SPARC in Human Tissues
Studies in murine tissues have indicated that SPARC is expressed at high levels in tissues undergoing mineralization, proliferation, remodeling, and/or steroidogenesis. To characterize the expression of the protein in human tissues, we selected a group of adult benign and malignant tissues. Immunostaining with SSP2 in human tissue was almost exclusively intracellular and reproduced the findings in mouse tissues with regard to many cell types; these data are summarized in Table 1 . Although SPARC binds to components of the ECM, it does not appear to be incorporated into the ECM per se. In agreement with previous investigations (25-27), we did not find significant staining of basement membrane or extracellular regions in any of the tissues examined. There were low to undetectable levels of immunoreactivity for SPARC in normal quiescent tissue. However, strong immunostaining was seen in fibrocytes and endothelial cells associated with tissues undergoing remodeling, both in benign and in neoplastic tissue. High levels of SPARC were seen in fibrous dysplasia of the vertebral body, in pleura undergoing reactive fibrosis, and in stromal fibrocytes associated with various malignancies that included melanoma and adenocarcinomas of liver, ovary, breast, and lung (Figures  2a-2c ). Additional mesenchymal cells that exhibited variable low to moderate levels of immunostaining included skeletal muscle cells, benign ovarian surface epithelial cells, and vascular smooth muscle cells (Figures 2d-2f ).
High levels of SPARC mRNA and protein are present in ossifying tissues and have been specifically associated with odontoblasts. chondrocytes, and perichondrial fibroblasts in the developing bones and teeth of murine, bovine, and human embryos (8.28). As expected, we found positive immunostaining in chondrocytes, in benign teratoma and benign chondroma, and in developing fetal bone ( Figure 3) .
One of the cell types in which expression of SPARC mRNA or protein has been consistently reported is the testicular Leydig cell (29) . We identified high levels of cytoplasmic immunoreactivity in Leydig cells and variable staining in Sertoli cells in normal testicular tissue (Figure 4a ). Our results in human tissue are consistent with those in mouse and indicate that SPARC is a prevalent protein product of testicular cells. Adrenocortical cells, ovarian follicular cells, and pancreatic islet cells ( Figure 4b ) are examples of other hormone-producing cells that showed positive immunostaining with SSP2. Although high expression of SPARC mRNA had previously been reported in mouse adrenocortical cells (7) . protein expression in these cells had not been detected with polyclonal antibodies against SPARC (6) . High levels of SPARC mRNA have been reported in the thecal cells around developing ovarian follicles in immature mice and in the corpora lutea (hormone-secreting granulosa cells and the endothelial cells of the capillary plexus) in pregnant female mice (7) . High levels of SPARC mRNA have also been identified in decidual cells of the mouse, and both mRNA and protein have been demonstrated in human decidua (20). We also found strong immunoreactivity in decidua and in placental syncytiotrophoblasts.
Many epithelial cells showed some degree of immunoreactivity with the antibody. The squamous epithelium of skin and the glandular epithelia of non-neoplastic uterus, breast, and gut exhibited a variable and usually low incidence of SPARC. From a selected series of fetal tissues (60-120 days' gestation), we observed SPARC protein in developing bone. the surface cells of chorionic villi, syncytiotrophoblasts, hepatocytes, developing skeletal muscle cells, ac-, .' . tive fibrocytes throughout the body and, rarely, in gut and bronchial epithelial cells.
SPARC Is Present in Human Neoplastic Tissue
Malignancies of mesenchymal cell origin consistently exhibited strong immunostaining with the SSP2 antibody. Osteosarcoma, giant-cell tumor of bone, malignant fibrous histiocytoma, angiosarcoma, leiomyosarcoma, and hemangioendothelioma were all moderately to highly positive ( Table 2 ). The giant or multinucleate cells of giant-cell tumor of bone, malignant fibrous histiocytoma, and pleomorphic sarcoma showed particularly strong immunoreactivity (Figure 5d ).
The pattern of immunostaining in epithelial tumors was more variable. Whereas the majority of epithelial tumors showed high levels of SPARC, others were completely negative ( Table 2 ). Since most of the malignant tumors we examined were of high grade, rigorous demonstration of an association between SPARC expression and tumor grade is not possible in these experiments. High tumor grade did not appear, however, to be consistent with a high level of SPARC expression, as has been previously suggested (20).
Many of the negative cases were high-grade tumors, and positive immunostaining was found in in situ carcinomas of breast. In the tumors that were negative for SPARC. we noted that the stroma associated with the neoplasm almost always contained strongly positive fibrous cells (Figures 2b and 2c ). We were able to compare the expression of SPARC in benign and malignant cells in tissue sections that contained both components. In the six breast, one endometrial, and two lung cancer cases that contained both benign and malignant epithelium, we found increased SPARC in the malignant cells over that seen in the benign glandular tissue ( Figure 6 ). SPARC was present, however, in benign breast epithelium. In two cases that did not contain cancer (one with apocrine metaplasia and one with fibroadenoma), the ductal epithelium was moderately reactive with the antibody. Benign glandular epithelium from lung, liver, prostate, and intestine in cases without tumor showed variable low immunostaining compared with that seen in malignant tumors of the same cell type.
Despite a documented association between SPARC expression and cell proliferation in murine embryos and adults (6), we did not find appreciable immunoreactivity for SPARC in the proliferative compartments of human normal gut or in skin. In fact, comparison of the pattern of PCNA with the distribution of SPARC revealed no apparent correlation. SPARC was present in the superficial cells of squamous epithelium, focally at the luminal surface of fetal gut, in pancreatic acinar and islet cells, and in brain astrocytes, cells in which proliferation is considered to be low ( Figure  7a ). SPARC was also present in many highly proliferative malignant cells. However, in cases such as ductal carcinoma in situ (DCIS) of breast, in which proliferating cells can be localized, the distri-bution of SPARC did not correlate with that of PCNA-positive cells (Figure 7b ).
Discussion
The biochemical properties and tissue distribution of SPARC indicate that it has complex biological functions in both mineralized and non-mineralized tissues. Although original reports focused on the increased expression of SPARC in human and bovine bone, it is clear that the biological functions of SPARC are not restricted to regulation of tissue mineralization. Expression of murine SPARC occurs earlier in development in non-ossifying tissues and is present in adult gut, testis, and mammary gland (6) . Our results support the concept of SPARC as a multifunctional protein and provide evidence for a distribution of SPARC in human tissues that is not restricted to a limited number of cell types.
The distribution of SPARC that we identified in human tissue can be summarized as follows: (a) SPARC was present at low levels in most glandular epithelia, fibrocytes, endothelial cells, skeletal muscle, vascular smooth muscle, astrocytes, and macrophages; (b) apparently higher levels of immunostaining were identified in chondrocytes, fibrocytes involved with repair or associated with neoplasia, multinucleate cells, testicular Leydig and Sertoli cells, and some malignant cell populations; (c) only cytoplasmic immunoreactivity was observed in all cell types; and (d) basement membranes were non-reactive with our anti-SPARC antibody. These results are consistent with the proposed model of SPARC as a transiently secreted protein that affects cell adhesion to components of the ECM but is itself not incorporated into the ECM (11).
The synthesis of SPARC by fibroblasts in vivo has been reported at sites of wound repair (30) . and considerable evidence exists for the production of SPARC by fibroblasts and endothelial cells in vitro (15, 26, 31, 32) . We contribute additional evidence that SPARC is expressed in tissues undergoing remodeling and repair. The low level of immunostaining for SPARC in inactive fibrocytes contrasts sharply with the staining intensity that we found in fibrocytes associated with active processes (Figure 2) . The function of SPARC in tissue repair might be related to the regulation of ECM deposition or assembly (33) .
Modulation of cell shape is another mechanism by which SPARC might function in tissue repair. SPARC has been shown to facilitate changes in cell shape that contribute to the release of cells from their ECM (11.34). Alterations in cell shape in vitro are related to the number and distribution of focal adhesions on the cell surface, and SPARC is known to diminish the number of focal adhesions in cultured bovine endothelial cells (35) . By disrupting cell-substrate contacts and facilitating the reorganization of cytoskeletal elements, SPARC appears to diminish the adhesive interactions between cells and their matrix (10) . These activities would be permissive for the cell proliferation andlor migration necessary during the remodeling process. Our finding that SPARC immunoreactivity is higher in many neoplastic cell populations compared to adjacent benign cellular counterparts indicates that an increase in SPARC levels might accompany the transition from a benign to a malignant phenotype. Other investigators have found enhanced levels of SPARC mRNA or protein in malignant tissues that include sarcomas and carcinomas (27.36). murine EHS tumors (37), and poorly differentiated endometrial adenocarcinomas (20).
A study of teratocarcinoma cells showed a 20-fold increase in SPARC mRNA during differentiation to a phenotype that resembles parietal endoderm. During implantation, these extraembryonic cells withdraw from the cell cycle, synthesize a basement membrane, and facilitate embryonic invasion of the uterine stroma (27) . Tissue invasion is a requisite feature of malignant cells and requires cell detachment and the release of certain enzymes that degrade basement membrane (19). SPARC is known to induce metalloproteinases (collagenase, stromelysin, and 9 2 KD gelatinase) that degrade both interstitial and basement membrane matrices (13). Moreover, in cultured endothelial cells, SPARC stimulates the production of plasminogen activator inhibitor4 (PAI-I), a serpin that regulates the activity of plasmin (17).
SPARC might also be involved in the development of a tumorassociated vascular network. A model based on the activity of SPARC in vitro has been proposed, in which the protein reduces the attachment of endothelial cells to ECM and results in an alteration of endothelial cell shape, proliferation, migration, and the formation of new cords and tubes (4) . We have identified SPARC in tumor cells and in stromal cells surrounding tumors; vessel formation related to malignancy might be initiated by the secretion of SPARC by one or more of these cell types. In virtually all tumors examined, the tumor cells andlor the associated fibrocytes and endothelial cells contained detectable levels of SPARC. If SPARC is active in malignant tissue, the staining pattern might reflect transient expression by tumor cells or cells of the surrounding stroma and possible paracrine regulation of cell behavior.
The function of SPARC in hormone-producing cells is not well understood. SPARC mRNA is present in cultured mouse Leydig cells, which are known to secrete SPARC protein in vitro (14). SPARC has been shown to increase "endothelial albumin flux in a dosedependent manner, without associated loss of cell viability, in bovine pulmonary artery endothelial cells (38). It is possible that SPARC regulates the permeability of the endothelial barrier in hormone-producing tissue to permit diffusion of hormones into the blood stream.
In our examination of human tissue, we did not find a clear association with proliferating cells and the presence of SPARC, although recent evidence indicates that SPARC might be involved, either directly or indirectly, in the regulation of cell proliferation. SPARC has been shown to retard the cell cycle in bovine aortic endothelial cells through inhibition of progression of cells from G1 to S-phase and to regulate the growth of cultured fibroblasts and endothelial cells in a concentration-dependent manner (9.39). It has been proposed that the inhibitory effect of SPARC on the cell cycle might be permissive for cell migration or differentiation, activities that are dependent on cessation of the cell cycle (4). If SPARC inhibits cell proliferation, it could be an important participant in the processes of cellular differentiation or senescence. SPARC mRNA is increased in experimental models of aging (40) and exhibits restricted but prominent expression during terminal differentiation of human keratinocytes in vivo (41) .
With an MAb against SPARC Domain I, we have demonstrated similarities in the distribution of SPARC between mouse and human and have identified additional human cell types that contain SPARC. The expression of SPARC/osteonectin in the mouse provided the first evidence in vivo that the protein participates in a variety of biological processes. Our results indicate a similar scope of activities in human tissues, including human tumors.
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